[{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"ACh receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"AazeinTX","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"NEO6860","moa":"TRPV1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"adMare BioInnovations \/ AazeinTX","highestDevelopmentStatusID":"4","companyTruncated":"adMare BioInnovations \/ AazeinTX"},{"orgOrder":0,"company":"Ceapro","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"PGX-YBG","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ceapro \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ McMaster University"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"OB-002","moa":"CCR5 pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"4","companyTruncated":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Data demonstrated that PGX-processed yeast beta glucan (PGX-YBG) is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models.

                          Product Name : PGX-YBG

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          May 23, 2023

                          Lead Product(s) : PGX-YBG

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : McMaster University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AazeinTx has acquired all rights to NEO6860, a clinical-stage TRPV1 antagonist in adMare’s technology portfolio. With a team at the University of Calgary led by Dr. Richard Wilson AazeinTx proposes to bring a pill-based form of NEO6860.

                          Product Name : NEO6860

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 17, 2021

                          Lead Product(s) : NEO6860

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : AazeinTX

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Results of new investigational in vitro data shows that two benzalkonium chloride preserved eye drops, LUMIFY® redness reliever eye drops and BESIVANCE® 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2 (S...

                          Product Name : Lumify

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 16, 2020

                          Lead Product(s) : Brimonidine Tartrate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Funding will support the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome (ARDS).

                          Product Name : AV-001

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          August 18, 2020

                          Lead Product(s) : Vasculotide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : US Department of Defense

                          Deal Size : $2.8 million

                          Deal Type : Funding

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).

                          Product Name : OB-002

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 30, 2020

                          Lead Product(s) : OB-002

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : National Research Council Industrial Research Assistance Program

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank